Product approval by the FDA is no longer the end of the line for new therapies and technologies. Innovators must prove value to government and private payers in order to generate a reimbursement revenue stream that covers research and development costs and provides adequate profits to fuel the next discovery’s translation and commercialization. To obtain a favorable coverage and payment decision, innovators must meet increasingly complex, demanding and often times opaque evidentiary requirements. During this frank discussion, the decision makers will focus on what outcomes payers are expecting to see from clinical trials, how they define “value,” how they see mechanisms like bundled payments and accountable care organizations (ACOs) being implemented, and how they measure impact on function and quality of life when they make their decisions.

Speakers:

Troyen A. Brennan, M.D., M.P.H.
Executive Vice President & Chief Medical Officer, CVS Health